No profile data available.
Adial Pharmaceuticals, Inc. (ADIL) is a healthcare company in the poison treatment pharmaceuticals industry, based in Glen Allen, United States, with about 5 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$7.98 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $10.24 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
Adial Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$10.24 million as of October 9, 2026.
Listed companies of a similar size in the same industry (poison treatment pharmaceuticals) include Aquestive Therapeutics, Inc. (AQST), Fennec Pharmaceuticals Inc. (FENC), Anebulo Pharmaceuticals, Inc. (ANEB), Addex Therapeutics Ltd (ADXN).